Rheumatoid arthritis clinical trials, in English

This study wants to obtain biologic materials from the blood, airways and/or urine of normal individuals and individuals with lung disease. The normal are used to establish a set of normal ranges for various parameters.

NCT01776398 · Official ClinicalTrials.gov record · Weill Medical College of Cornell University

Rheumatoid arthritis (RA) is a common disease with approximately 1% prevalence. RA is also a chronic, progressive disease with no cure.

NCT03414502 · Official ClinicalTrials.gov record · University of Nebraska

In a previous exploratory study, the investigators observed an effect on disease activity outcomes of anti-inflammatory diet. The investigators also observed change in microbiome and circulating metabolites.

NCT04748809 · Official ClinicalTrials.gov record · University of California, San Diego

This trial will study the safety and how well it works of intravenous infusion and intra-articular injection of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells for the treatment of Rheumatoid Arthritis

NCT05003934 · Official ClinicalTrials.gov record · The Foundation for Orthopaedics and Regenerative Medicine

Population Patients with a diagnosis of Rheumatoid Arthritis (RA), moderate or high clinical disease activity (CDAI\>10) despite conventional synthetic (cs)DMARD(s) or bs-ts-DMARDs therapy for ≥3 months, and a maximum of 2 swollen joints (out of 44 joints) Study design randomly assigned multicentre, parallel-arm clinical study Primary objective Non-inferiority of the experimental arm (i.e. clinical therapy together with ultrasound guided treatment decision) in comparison to the control arm (clinically guided decision) concerning the proportion of patients reaching low disease activity (CDAI ≤10) and a minimal clinical important improvement (MCII: improvement of ≥6 points if starting from moderate disease activity, any case starting from high disease activity and achieving low disease activity) or remission according to ACR/EULAR index-based remission criteria (CDAI ≤2.8/Boolean remission) at week 24.

NCT05717179 · Official ClinicalTrials.gov record · Italian Society for Rheumatology

The goal of this pragmatic embedded open-label, 2 x 2 factorial phase II randomly assigned controlled trial is to evaluate strategies to improve COVID-19 booster and influenza vaccine immunogenicity in people living with immunocompromising conditions (PLIC). The main questions it aims to answer are: 1.

NCT06599658 · Official ClinicalTrials.gov record · McGill University Health Centre/Research Institute of the McGill University Health Centre

The purpose of this research is to gather clinical and radiographic (X-ray) information about EMPHASYS™ acetabular shell (also called a hip 'cup') placement in total hip replacement surgery using a non-invasive surgical navigation system called VELYS™ hip navigation system with CUPTIMIZE™ Advanced Hip-Spine Analysis software. Data collected in this study will be compared with data collected from implantations using different cup positioning instrumentation and techniques to assess performance.

NCT06631638 · Official ClinicalTrials.gov record · DePuy Orthopaedics

This is an open-label, multi-ascending dose (MAD) phase 1 study, with dose expansion at selected doses, in adult patients with select autoimmune rheumatic diseases including systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). The purpose of the study is to identify possible optimal dose(s) by assessing the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary clinical response of SAR448501/DR-0201.

NCT06647069 · Official ClinicalTrials.gov record · Sanofi

This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomly assigned dose escalation and dose expansion basket study to determine the whether it is safe and how hard side effects are to live with of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with autoimmune diseases.

NCT06733935 · Official ClinicalTrials.gov record · Nkarta, Inc.

Background: Autoimmune diseases can be caused by genes people inherit from their parents. The gene changes that cause these diseases have been well studied in people with European and Asian ancestors.

NCT06948110 · Official ClinicalTrials.gov record · National Human Genome Research Institute (NHGRI)

This study evaluates the safety and how well it works of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), etc. Aproximately 6-12 patients aged 18-65 will receive a single infusion of YTS109 cells (1.5×10⁶ cells/kg).

NCT06978647 · Official ClinicalTrials.gov record · China Immunotech (Beijing) Biotechnology Co., Ltd.

This study wants to assess the incidence of rheumatologic flares, changes in pain scores (VAS), changes in functional outcomes (PROMIS), wound complications, surgical site infections, and return trips to the operating room for rheumatology patients following shoulder replacements, comparing those who stop their immunosuppressants preoperatively for the same amount of time as suggested in the literature for hip and knee arthroplasty versus those who hold the medications for a shorter period of time preoperatively.

NCT07138898 · Official ClinicalTrials.gov record · NYU Langone Health

This open-label, Phase I study will assess the whether it is safe and how hard side effects are to live with of surovatamig and characterise its PK and PD following subcutaneous administration to participants with RA or SLE.

NCT07201558 · Official ClinicalTrials.gov record · AstraZeneca

Background: Sjogren disease is an autoimmune disease - that is, a disease that causes the body's immune system to attack its own organs and tissues. Sjogren disease can affect the kidneys, lungs, or other organs.

NCT07281456 · Official ClinicalTrials.gov record · National Institute of Dental and Craniofacial Research (NIDCR)

This trial is a Phase 1b/2, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to measure the whether it is safe and how hard side effects are to live with in adult participants with systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM), or difficult-to-treat rheumatoid arthritis (D2T RA).

NCT07295847 · Official ClinicalTrials.gov record · AstraZeneca

This study looks at a study medicine called MK-1045 in people with lupus and rheumatoid arthritis (RA). The main goal of the study is to learn about the safety of MK-1045 and if people tolerate it when they receive it at different dose levels (amounts).

NCT07363590 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

This is a Phase 2 randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment study with a total duration of 32 weeks from Screening to End-of-Study (EOS) Visit. Approximately 180 participants are planned to be enrolled.

NCT07409103 · Official ClinicalTrials.gov record · Elevara Medicines Limited

This study wants to measure the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the preliminary evidence of disease-modifying effect of BMS-986528 in participants with refractory, difficult-to-treat rheumatoid arthritis (RA).

NCT07412704 · Official ClinicalTrials.gov record · Bristol-Myers Squibb

This is a multicenter, randomly assigned, neither you nor the study doctors know who gets the real treatment, parallel, dummy treatment (placebo)- and active comparator- controlled clinical study conducted in patients with moderately to severely active RA and an inadequate response to at least one DMARD, designed to assess the how well it works and safety of GenSci120 injection in this patient population. The study consists of a screening period (≤ 4 weeks), a compared with a dummy treatment treatment period (14 weeks), an extension treatment period (14 weeks), and a follow-up period (10 weeks), with a total of 17 scheduled visits.

NCT07423533 · Official ClinicalTrials.gov record · Changchun GeneScience Pharmaceutical Co., Ltd.

Rheumatoid arthritis (RA) and spondyloarthritis (SpA), including psoriatic arthritis (PsA), are chronic painful diseases that impair quality of life. Disease-modifying antirheumatic drugs (DMARDs) are used to control disease activity, reduce functional disability, and improve prognosis.

NCT07460739 · Official ClinicalTrials.gov record · Assistance Publique - Hôpitaux de Paris

This is a Phase 1, first in human study to measure the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of JADE201 compared to dummy treatment (placebo) in participants with Rheumatoid Arthritis

NCT07533955 · Official ClinicalTrials.gov record · Jade Biosciences, Inc.

PREVENER is a randomly assigned, open-label, multicenter, phase IV clinical trial designed to measure the how well it works and safety of a carotid ultrasound-based strategy for the primary prevention of cardiovascular events in patients with inflammatory rheumatic diseases (IRD). Patients with IRD, including rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis (AxSpA), and systemic lupus erythematosus (SLE), have a 50% higher risk of cardiovascular (CV) events compared to the general population.

NCT07611747 · Official ClinicalTrials.gov record · Instituto de Investigación Marqués de Valdecilla

This first-in-human study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of HBM7020. The study will enroll healthy participants at low doses, followed by participants with moderate to severe autoimmune diseases with predominant B-cell involvement.

NCT07649265 · Official ClinicalTrials.gov record · Otsuka Pharmaceutical Development & Commercialization, Inc.

This study wants to measure the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary clinical activity of CND319 in healthy adult participants and patients with rheumatic diseases.

NCT07712939 · Official ClinicalTrials.gov record · Candid Therapeutics

This study is designed to assess the safety, pharmacokinetics (PK), and biomarker effects of PTC844 compared to dummy treatment (placebo) in participants with active rheumatoid arthritis (RA).

NCT07779616 · Official ClinicalTrials.gov record · PTC Therapeutics

Background: Rheumatic diseases can affect the joints, ligaments, tendons, bones, muscles, and skin. They can also cause inflammation, damage body tissues, and change nerve signals in the brain.

NCT07829497 · Official ClinicalTrials.gov record · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by progressive joint damage and bone erosion. Accurate assessment of RA bone erosion risk (RABER) and appropriate disease-modifying antirheumatic drug (DMARD) selection are critical to preventing irreversible disability.

NCT07914907 · Official ClinicalTrials.gov record · Guang'anmen Hospital of China Academy of Chinese Medical Sciences